JP2014519524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519524A5 JP2014519524A5 JP2014515918A JP2014515918A JP2014519524A5 JP 2014519524 A5 JP2014519524 A5 JP 2014519524A5 JP 2014515918 A JP2014515918 A JP 2014515918A JP 2014515918 A JP2014515918 A JP 2014515918A JP 2014519524 A5 JP2014519524 A5 JP 2014519524A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- seq
- heavy chain
- amino acid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496249P | 2011-06-13 | 2011-06-13 | |
| US61/496,249 | 2011-06-13 | ||
| PCT/US2012/042068 WO2012174001A1 (en) | 2011-06-13 | 2012-06-12 | Anti-psgl-1 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519524A JP2014519524A (ja) | 2014-08-14 |
| JP2014519524A5 true JP2014519524A5 (https=) | 2015-07-30 |
| JP6180408B2 JP6180408B2 (ja) | 2017-08-16 |
Family
ID=47357432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515918A Active JP6180408B2 (ja) | 2011-06-13 | 2012-06-12 | 抗ｐｓｇｌ−１抗体およびその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20130209449A9 (https=) |
| EP (2) | EP2718325A4 (https=) |
| JP (1) | JP6180408B2 (https=) |
| KR (1) | KR102103036B1 (https=) |
| CN (3) | CN108892726A (https=) |
| AU (1) | AU2012271845B2 (https=) |
| BR (1) | BR112013031892A2 (https=) |
| CA (1) | CA2838952C (https=) |
| CL (1) | CL2013003570A1 (https=) |
| CO (1) | CO6940376A2 (https=) |
| EC (1) | ECSP14013132A (https=) |
| IL (2) | IL229844B (https=) |
| MX (1) | MX358447B (https=) |
| NZ (1) | NZ619524A (https=) |
| PH (1) | PH12013502568B1 (https=) |
| RU (1) | RU2650817C2 (https=) |
| SG (1) | SG10201604767TA (https=) |
| TW (1) | TWI643872B (https=) |
| UA (1) | UA114712C2 (https=) |
| WO (1) | WO2012174001A1 (https=) |
| ZA (1) | ZA201400209B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| UY28886A1 (es) | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| ES2655833T3 (es) | 2004-05-11 | 2018-02-21 | AbGenomics Coöperatief U.A. | Epítopos que inducen la muerte de células T |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| PT3166636T (pt) * | 2014-07-08 | 2021-06-29 | Sanford Burnham Med Res Inst | Moduladores de psgl-1 e utilizações dos mesmos |
| IL260289B (en) * | 2016-01-08 | 2022-08-01 | Bioalliance Cv | Tetravalent anti-psgl-1 antibodies and uses thereof |
| WO2017214941A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种提升SelP基因表达水平的慢病毒载体及其应用 |
| KR20250159733A (ko) | 2017-01-11 | 2025-11-11 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI832600B (zh) * | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| BR112020019083A2 (pt) | 2018-03-21 | 2020-12-29 | Five Prime Therapeutics, Inc. | Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer |
| PE20210687A1 (es) | 2018-07-11 | 2021-04-08 | Bristol Myers Squibb Co | Anticuerpos de union a vista a ph acido |
| CN112740043A (zh) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
| JP7317379B2 (ja) * | 2019-01-04 | 2023-07-31 | 国立大学法人京都大学 | 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法 |
| CA3141334A1 (en) * | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| KR20230015365A (ko) * | 2020-05-22 | 2023-01-31 | 포르미콘 아게 | Ace2 융합 단백질 및 이의 용도 |
| CN113667015B (zh) * | 2021-08-20 | 2022-10-11 | 北京康特泊瑞生物医药科技股份公司 | 靶向psgl-1蛋白的抗体及其用途 |
| US12290565B2 (en) | 2021-11-17 | 2025-05-06 | Altrubio Inc. | Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers |
| AU2023343549A1 (en) * | 2022-09-13 | 2025-03-20 | Tetherex Pharmaceuticals Corporation | Antibodies, compositions, and methods of treatment |
| WO2025106784A1 (en) * | 2023-11-17 | 2025-05-22 | Altrubio Inc. | Anti-psgl-1 antibodies and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
| US5378464A (en) | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
| US5690933A (en) | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
| US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
| US5972625A (en) | 1991-05-06 | 1999-10-26 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
| ES2131107T3 (es) | 1992-03-17 | 1999-07-16 | Novartis Ag | Anticuerpos obtenidos mediante ingenieria genetica. |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| WO1994014836A1 (en) | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
| DE69415154T2 (de) | 1993-01-25 | 1999-07-29 | Dana-Farber Cancer Institute, Inc., Boston, Mass. | Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen |
| WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| KR100523506B1 (en) | 1995-08-03 | 2005-10-24 | Peptide and O-glycan inhibitors of selectin mediated inflammation | |
| US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
| WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2347119A1 (en) | 1998-10-30 | 2000-05-11 | Genetics Institute, Inc. | Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
| DE60118362T2 (de) | 2000-05-19 | 2007-05-24 | The Center for Blood Research, Inc., Boston | VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN |
| EP1325123A4 (en) | 2000-09-12 | 2004-07-21 | Inst Genetics Llc | STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS |
| US20040001839A1 (en) | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040002450A1 (en) | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| EP1406930A4 (en) | 2000-12-29 | 2007-01-10 | Savient Pharmaceuticals Inc | "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF" |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| WO2004003166A2 (en) | 2002-07-01 | 2004-01-08 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| CA2531283A1 (en) | 2003-06-30 | 2005-01-20 | Bio-Technology General (Israel) Ltd. | Specific human antibodies |
| CN1922316B (zh) * | 2003-12-25 | 2011-03-23 | 协和发酵麒麟株式会社 | 抗cd40抗体突变体 |
| US7544487B2 (en) * | 2004-02-13 | 2009-06-09 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic RNAses |
| PT1737891E (pt) * | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| UY28886A1 (es) * | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| ES2655833T3 (es) | 2004-05-11 | 2018-02-21 | AbGenomics Coöperatief U.A. | Epítopos que inducen la muerte de células T |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI380996B (zh) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP2046833B9 (en) * | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| SI2132230T1 (sl) * | 2007-03-22 | 2014-07-31 | Genentech, Inc. | Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE |
| ES2593484T3 (es) * | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| JP6071165B2 (ja) * | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| CA2687896A1 (en) | 2007-06-05 | 2008-12-18 | Yale University | Antibody directed against the d4 ig-like domain of the kit receptor |
| CA2697612A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US20110086366A1 (en) * | 2008-02-22 | 2011-04-14 | Genmab A/S | Methods for assessing the risk of adverse events upon treatment with igg4 antibodies |
| US7833530B2 (en) * | 2008-05-15 | 2010-11-16 | Selexys Pharmaceuticals Corporation | Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies |
| US20100233157A1 (en) * | 2009-03-12 | 2010-09-16 | Osorio Lyda M | Human antibodies against human fas and their use |
| BR112012007875A2 (pt) | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| AU2015277100A1 (en) | 2014-06-20 | 2017-02-02 | Abgenomics International Inc. | HER2 antibody-drug conjugates |
-
2012
- 2012-06-12 EP EP12799966.2A patent/EP2718325A4/en not_active Ceased
- 2012-06-12 KR KR1020147000603A patent/KR102103036B1/ko active Active
- 2012-06-12 PH PH1/2013/502568A patent/PH12013502568B1/en unknown
- 2012-06-12 JP JP2014515918A patent/JP6180408B2/ja active Active
- 2012-06-12 NZ NZ619524A patent/NZ619524A/en unknown
- 2012-06-12 US US13/494,398 patent/US20130209449A9/en not_active Abandoned
- 2012-06-12 CN CN201810722769.2A patent/CN108892726A/zh active Pending
- 2012-06-12 CN CN201280039482.0A patent/CN103732626A/zh active Pending
- 2012-06-12 BR BR112013031892A patent/BR112013031892A2/pt not_active Application Discontinuation
- 2012-06-12 MX MX2013014814A patent/MX358447B/es active IP Right Grant
- 2012-06-12 RU RU2013158083A patent/RU2650817C2/ru active
- 2012-06-12 WO PCT/US2012/042068 patent/WO2012174001A1/en not_active Ceased
- 2012-06-12 UA UAA201314798A patent/UA114712C2/uk unknown
- 2012-06-12 EP EP21168455.0A patent/EP3925978A1/en active Pending
- 2012-06-12 AU AU2012271845A patent/AU2012271845B2/en active Active
- 2012-06-12 SG SG10201604767TA patent/SG10201604767TA/en unknown
- 2012-06-12 CA CA2838952A patent/CA2838952C/en active Active
- 2012-06-12 CN CN202211394154.4A patent/CN116063522A/zh active Pending
- 2012-06-13 TW TW101121146A patent/TWI643872B/zh active
-
2013
- 2013-04-17 US US13/865,085 patent/US20130251708A1/en not_active Abandoned
- 2013-12-08 IL IL229844A patent/IL229844B/en unknown
- 2013-12-12 CL CL2013003570A patent/CL2013003570A1/es unknown
-
2014
- 2014-01-09 ZA ZA2014/00209A patent/ZA201400209B/en unknown
- 2014-01-13 CO CO14004726A patent/CO6940376A2/es unknown
- 2014-01-13 EC ECSP14013132 patent/ECSP14013132A/es unknown
-
2021
- 2021-08-30 US US17/460,883 patent/US11897964B2/en active Active
- 2021-10-14 IL IL287270A patent/IL287270A/en unknown
-
2023
- 2023-12-26 US US18/396,607 patent/US20240124604A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519524A5 (https=) | ||
| RU2013158083A (ru) | Анти-psgl-1-антитела и их применение | |
| JP2014505463A5 (https=) | ||
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| RU2487723C2 (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| FR22C1052I1 (fr) | Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes | |
| RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| JP2013545438A5 (https=) | ||
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| CO2017011486A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
| JP2010526028A5 (https=) | ||
| SI2771031T1 (en) | Humanized antibodies that recognize alpha-synuclein | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| JP2015535828A5 (https=) | ||
| RU2017102193A (ru) | Конструкции полиспецифических антител | |
| CA2813849C (en) | Secukinumab for use in the treatment of ankylosing spondylitis | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2015514090A5 (https=) | ||
| JP2008527989A5 (https=) | ||
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba | |
| IN2014CN03936A (https=) | ||
| RU2016133463A (ru) | Гуманизированные антитела с повышенной стабильностью | |
| SI2593128T1 (en) | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures |